This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A NEW MYDRIATIC AND CYCLOPLEGIC DRUG

KENNETH C. SWAN, M.D.; NORMAN G. WHITE, M.S.

Arch Ophthal. 1945;33(1):16-22.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

There has been need in ophthalmology for new mydriatic and cycloplegic drugs. Hypersensitivity and idiosyncrasies to atropine and its derivatives are not uncommon. Also, the dosage of the more potent members of the group is limited by undesirable systemic effects, e. g., excitation and depression of the central nervous system, flushed face and drying of secretions. Finally, the ocular effects of atropine and scopolamine are unduly prolonged and are not readily counteracted. Recently we have synthesized the first substitutes for the atropine series effective on the eye.¹ The new mydriatic and cycloplegic drugs are surface active carbamic acid esters of the choline type and, therefore, are chemically unrelated to atropine. The ocular effects of the first of the new class of drugs have been reported previously.² Herein are described the ocular pharmacologic effects and some clinical applications of dibutoline, a name for the latest and most effective member . . . [Full Text PDF of this Article]

Author Affiliations
IOWA CITY

From the Department of Ophthalmology, State University of Iowa College of Medicine.

Footnotes
This paper represents part of a study being conducted under a grant from the John and Mary R. Markle Foundation.

Read before the Section on Ophthalmology, at the Ninety-Fourth Annual Session of the American Medical Association, June 15, 1944.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?